These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 14608516

  • 21. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
    Dulin BR, Krum H.
    Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210
    [Abstract] [Full Text] [Related]

  • 22. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S.
    Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
    [Abstract] [Full Text] [Related]

  • 23. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS.
    Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931
    [Abstract] [Full Text] [Related]

  • 24. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
    van Diepen S, Reynolds HR, Stebbins A, Lopes RD, Džavík V, Ruzyllo W, Geppert A, Widimsky P, Ohman EM, Parrillo JE, Dauerman HL, Baran DA, Hochman JS, Alexander JH.
    Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033
    [Abstract] [Full Text] [Related]

  • 25. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
    Hennekens CH, Kowalczykowski M, Hollar D.
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):149-52. PubMed ID: 16891293
    [Abstract] [Full Text] [Related]

  • 26. [Is it always necessary to use triple combination in the treatment of patients with chronic cardiac failure? Choice of the third neurohormonal blocker].
    Belenkov IuN, Mareev VIu, Skvortsov AA.
    Ter Arkh; 2008 Jun; 80(9):5-12. PubMed ID: 19555028
    [No Abstract] [Full Text] [Related]

  • 27. Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure.
    Khattar RS.
    Minerva Cardioangiol; 2003 Apr; 51(2):143-54. PubMed ID: 12783070
    [Abstract] [Full Text] [Related]

  • 28. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
    van de Wal RM, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Eur Heart J; 2005 Nov; 26(22):2361-7. PubMed ID: 16105846
    [Abstract] [Full Text] [Related]

  • 29. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Int J Cardiol; 2006 Jan 26; 106(3):367-72. PubMed ID: 16337046
    [Abstract] [Full Text] [Related]

  • 30. An approach to heart failure and diabetes mellitus.
    Fonarow GC.
    Am J Cardiol; 2005 Aug 22; 96(4A):47E-52E. PubMed ID: 16098844
    [Abstract] [Full Text] [Related]

  • 31. ACE inhibitors and beta blockers in chronic congestive cardiac failure: therapeutic basis.
    Manoria PC, Manoria P.
    J Indian Med Assoc; 2003 May 22; 101(5):311-2, 315. PubMed ID: 14575221
    [Abstract] [Full Text] [Related]

  • 32. [ACE inhibitors, beta blockers, AT-1 antagonists in heart failure. Right dosage and combination].
    Fliri M.
    MMW Fortschr Med; 2002 Nov 28; 144(48):38-43. PubMed ID: 12532542
    [Abstract] [Full Text] [Related]

  • 33. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R, Palmer BF.
    Am J Nephrol; 2008 Nov 28; 28(3):372-80. PubMed ID: 18073461
    [Abstract] [Full Text] [Related]

  • 34. Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?
    Pitt B.
    Curr Heart Fail Rep; 2009 Jun 28; 6(2):112-6. PubMed ID: 19486595
    [Abstract] [Full Text] [Related]

  • 35. The effects of angiotensin receptor antagonists on mortality and morbidity in heart failure--and an interaction with beta blockade.
    Coats AJ.
    Int J Cardiol; 2001 Jan 28; 77(1):1-4. PubMed ID: 11150619
    [No Abstract] [Full Text] [Related]

  • 36. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G, Gorini M, Maggioni AP, Di Lenarda A, Area Scompenso ANMCO, Firenze.
    G Ital Cardiol (Rome); 2007 Feb 28; 8(2):102-6. PubMed ID: 17402354
    [Abstract] [Full Text] [Related]

  • 37. Heart failure: recent advances in prevention and treatment.
    Fonarow GC.
    Rev Cardiovasc Med; 2000 Feb 28; 1(1):25-33, 54. PubMed ID: 12457149
    [Abstract] [Full Text] [Related]

  • 38. Advances in the treatment of heart failure with a preserved ejection fraction.
    Das A, Abraham S, Deswal A.
    Curr Opin Cardiol; 2008 May 28; 23(3):233-40. PubMed ID: 18382212
    [Abstract] [Full Text] [Related]

  • 39. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
    McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J, Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators.
    Circ Heart Fail; 2008 May 28; 1(1):17-24. PubMed ID: 19808266
    [Abstract] [Full Text] [Related]

  • 40. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun 28; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.